Jan Berger, MD, MJ, president & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says that historically medication adherence, when it pertained to PBMs, was really just about selling pills-it was an isolated, siloed issue.
Jan Berger, MD, MJ, president & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says that historically medication adherence, when it pertained to PBMs, was really just about selling pills—it was an isolated, siloed issue. However, pharmacy benefit managers (PBMs) began to recognize that clients were looking at adherence in a bigger, broader sense as they realized how adherence affected their lives, out-of-pocket costs, and workability.
Dr Berger also says that one of the newer areas PBMs are focusing on are medication adherence outcomes.
“Are people take their medications, and if they’re not, what are those barriers that need to be overcome in order to take it?" asks Dr Berger. "So like the rest of healthcare, we are going from a process-oriented world, to an outcomes-oriented world.”
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More